Chris Naprawa, the President of Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH), visited Midas Letter to address the internet rumours speculating that the company has not registered its seeds with the Colombian regulators when, in contrast, Khiron has five separate strains registered at this moment with further strains soon to start the process. While misguided rumours circulate online, Khiron is still the dominant integrated cannabis company in Colombia. The company’s potential addressable patient network is over 1 million individuals represented by over 5,000 doctors through six medical association endorsements. Khiron’s Wellness line, Kuida, also has distribution agreements with the largest retail outlets throughout Colombia, with over 176 points of sale. The Khiron President is not focused on the summer doldrum market selloff and is concentrating his efforts towards the company’s patients and consumers by executing on growing the business.
©2019 Midas Letter. All Rights Reserved.